For the subgroup analysis of 30-day mortality based on receipt of additional prostate cancer therapy (patients were grouped by receipt of ARI-1 or ARI-2, abiraterone in combination with prednisone, and chemotherapy), a descriptive analysis prior to PSM is presented in Table 3 and in eTable 3 in the Supplement. This evidence concerns the gene ARIH2 and Familial prostate cancer.